Sleep Medicine
Volume 10, Issue 1 , Pages 55-59 , January 2009

The effects of ramelteon in a first-night model of transient insomnia

  • Gary Zammit

      Affiliations

    • Clinilabs Sleep Disorder Institute, 423 West 55th Street, New York, NY 10019, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 994 5100; fax: +1 212 994 5101.
    • ,
  • Howard Schwartz

      Affiliations

    • Miami Research Associates, 6141 Sunset Drive, Ste. 301, Miami, FL 33143, USA
    • ,
  • Thomas Roth

      Affiliations

    • Henry Ford Hospital, Sleep Disorders and Research Center, 2799 West Grand Boulevard, CFP-3 Detroit, MI 48202, USA
    • ,
  • Sherry Wang-Weigand

      Affiliations

    • Takeda Global Research and Development Center, 1 Takeda Parkway, Deerfield, IL 60015, USA
    • ,
  • Steve Sainati

      Affiliations

    • Takeda Global Research and Development Center, 1 Takeda Parkway, Deerfield, IL 60015, USA
    • ,
  • Jeff Zhang

      Affiliations

    • Takeda Global Research and Development Center, 1 Takeda Parkway, Deerfield, IL 60015, USA

Received 2 January 2008 ,Revised 7 April 2008 ,Accepted 9 April 2008.

References 

  1. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301–310
  2. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102
  3. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005;28:303–307
  4. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose–response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17–24
  5. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7:312–318
  6. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23:1005–1014
  7. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3:495–504
  8. Roehrs T, Zorick F, Roth T. Transient and short-term insomnias. In:  Kryger M,  Roth T,  Dement WC editor. Principles and practice of sleep medicine. 3rd ed.. Philadelphia, PA: WB Saunders Company; 2000;p. 624–632
  9. Agnew HW, Webb WB, Williams RL. The first night effect: an EEG study of sleep. Psychophysiology. 1966;2:263–266
  10. Erman MK, Loewy DB, Scharf MB. Effects of temazepam 7.5mg and temazepam 15mg on sleep maintenance and sleep architecture in a model of transient insomnia. Curr Med Res Opin. 2005;21:223–230
  11. Erman M, Erwin C, Gengo F, Jamieson A, Lemmi H, Mahowald M, et al. Comparative efficacy of zolpidem and temazepam in transient insomnia. Hum Psychopharmacol. 2001;16:169–176
  12. Rosenberg R, Caron J, Roth T, Amato D. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med. 2005;6:15–22
  13. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995;18:246–251
  14. DeMicco M, Wang-Weigand S, Zhang J. Long-term therapeutic effects of ramelteon treatment in adults with chronic insomnia: a 1-year study. Sleep. 2006;29(Suppl.):A234;[abstract]
  15. Roehrs T, Vogel G, Sterling W, Roth T. Dose effects of temazepam in transient insomnia. Arzneimittelforschung. 1990;40:859–862
  16. Lamphere J, Roehrs T, Zorick F, Koshorek G, Roth T. The dose effects of zopiclone. Hum Psychopharmacol. 1989;4:41–46
  17. Rush CR, Frey JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology. 1999;145:39–51
  18. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006;63:1149–1157
  19. Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006;46:140–148

PII: S1389-9457(08)00145-7

doi: 10.1016/j.sleep.2008.04.010

Sleep Medicine
Volume 10, Issue 1 , Pages 55-59 , January 2009

Article Tools